文献速递白血病

抗代谢药物剂量强度与急性淋巴细胞白血病患儿不良结局:COG-AALL03N1报告

Antimetabolite dose intensity and adverse outcomes in children with acute lymphoblastic leukemia: a COG-AALL03N1 report.
PubMed 文献 · Blood · 2024-01-01

基于COG-AALL03N1数据,纳入644例TPMT和NUDT15野生型ALL维持治疗患儿,29.3%暴露于高剂量强度。高剂量强度与血液学毒性风险增加相关(OR 2.1,95%CI 1.4-3.1),在依从者中关联更强(OR 2.9,95%CI 1.6-5.1)。高剂量强度在依从者中与复发风险增加相关(aHR 2.4,95%CI 1.0-5.5),非依从者中无此关联。

要点

  • 高剂量强度与血液学毒性风险增加相关,依从者中关联更强。
  • 高剂量强度在依从者中与复发风险增加相关,非依从者中无关联。
  • 维持治疗中超过方案剂量的剂量递增应在评估依从性后谨慎进行。

核心结论

  • 在TPMT和NUDT15野生型ALL维持治疗患儿中,高剂量强度与血液学毒性风险增加相关,且在依从者中与复发风险增加相关。
  • 作者认为,ALL维持治疗中超过方案剂量的剂量递增应在评估依从性后谨慎进行。

研究设计与样本

  • 基于儿童肿瘤协作组(COG)AALL03N1数据的研究,纳入644例TPMT和NUDT15野生型ALL维持治疗患儿。
  • 高剂量强度表型定义为前4研究月内6-巯基嘌呤(6-MP)或甲氨蝶呤(MTX)剂量强度≥110%,或入组时6-MP或MTX剂量强度100%-110%且4个月内增加≥25%;其余为正常剂量强度表型。
  • 63.7%的研究参与者有6-MP依从性数据,依从者定义为中位依从性≥85%,非依从者为<85%。
  • 多变量分析调整了社会人口学和临床预后因素。

主要发现

  • 644例患者中29.3%暴露于高剂量强度。
  • 高剂量强度与血液学毒性风险增加相关:整个队列OR 2.1(95%CI 1.4-3.1),依从者OR 2.9(95%CI 1.6-5.1),非依从者OR 2.1(95%CI 0.4-10.1)。
  • 高剂量强度与复发风险:整个队列aHR 1.4(95%CI 0.8-2.4),依从者aHR 2.4(95%CI 1.0-5.5),非依从者aHR 0.9(95%CI 0.2-3.8)。

临床怎么用

  • ALL维持治疗中超过方案剂量的剂量递增应在评估依从性后谨慎进行(作者建议)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The association between antimetabolite dose intensity (DI) and adverse events among children receiving maintenance therapy for acute lymphoblastic leukemia (ALL) remains unclear, especially in the context of antimetabolite adherence. Using Children's Oncology Group AALL03N1 data, we examined the association between high DI during the first 4 study months and (i) treatment-related toxicities during the subsequent 2 study months; and (ii) relapse risk. Patients were classified into a high DI phenotype (either 6-mercaptopurine [6-MP] or methotrexate [MTX] DI ≥110% during the first 4 study months, or 6-MPDI or MTXDI 100%-110% at study enrollment and ≥25% increase over the 4 study months) and normal DI phenotype (all others). Only patients with wild-type TPMT and NUDT15 were included. 6-MP adherence data were available for 63.7% of study participants and used to stratify as adherent (median adherence ≥85%) and nonadherent (median adherence <85%) participants. Multivariable analyses were adjusted for sociodemographic and clinical prognosticators. Of the 644 patients, 29.3% were exposed to high DI. High DI was associated with a 2.1-fold greater odds of hematologic toxicity (95% confidence interval [CI] = 1.4-3.1; reference: normal DI) in the entire cohort and 2.9-fold higher among adherers (95% CI = 1.6-5.1); odds were comparable among nonadherers (2.1-fold; 95% CI = 0.4-10.1). Although high DI was not associated with relapse in the entire cohort (adjusted hazard ratio [aHR] = 1.4; 95% CI = 0.8-2.4), it was associated with a greater hazard of relapse among adherent participants (aHR = 2.4; 95% CI = 1.0-5.5) but not among nonadherent participants (aHR = 0.9; 95% CI = 0.2-3.8). Dose escalation above protocol doses during maintenance therapy for ALL should be done cautiously after assessing adherence to prescribed therapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Wadhwa A, Chen Y, Hageman L, et al. Antimetabolite dose intensity and adverse outcomes in children with acute lymphoblastic leukemia: a COG-AALL03N1 report. Blood. 2024. PMID: 39190431. doi:10.1182/blood.2024024455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。